title: Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery.
abstract: HER2-positive breast cancer is a known risk factor for CNS metastases, and the use of trastuzumab in the adjuvant setting does not prevent brain metastases. The purpose of this study is to compare outcomes in HER2-positive and HER2-negative intracranial disease treated with stereotactic radiosurgery (SRS). Among 57 breast cancer patients with brain metastases, 28 patients were HER2-positive. All patients were treated with SRS as their first treatment modality for CNS metastases. The median dose was 20 Gy (range 12-20 Gy). Statistical analysis was performed using the Kaplan-Meier method and χ (2) test. With a median follow-up of 11.0 months, the median time to progression in the HER2-positive group compared with the HER2-negative group was 7 versus 11 months (p = 0.080), respectively. Salvage therapy was performed in 50 % of HER2-positive patients compared with 21 % of HER2-negative patients (p = 0.02). The median OS for the HER2-positive group compared with the HER2-negative group was 22 versus 12 months (p = 0.053). Stereotactic radiosurgery results in excellent local control in the treatment for breast cancer brain metastases. Compared with HER2-negative disease, HER2-positive disease appears to show higher rates of intracranial relapse despite better overall survival rates. This data suggests that we need effective adjuvant therapy to prevent and treat brain metastases in HER2-positive patients.
authors.affiliation: Department of Radiation Oncology, New York University Cancer Institute, New York, NY, 10016, USA.
authors.forename: Moses
authors.initials: M
authors.lastname: Tam
authors.forename: Ashwatha
authors.initials: A
authors.lastname: Narayana
authors.forename: Shahzad
authors.initials: S
authors.lastname: Raza
authors.forename: Saroj
authors.initials: S
authors.lastname: Kunnakkat
authors.forename: John G
authors.initials: JG
authors.lastname: Golfinos
authors.forename: Erik C
authors.initials: EC
authors.lastname: Parker
authors.forename: Yelena
authors.initials: Y
authors.lastname: Novik
mesh_terms: D001932:Brain Neoplasms / Q000209:etiology / Q000378:metabolism* / Q000401:mortality / Q000628:therapy*; D001943:Breast Neoplasms / Q000150:complications / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016634:Radiosurgery / Q000009:adverse effects*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human